AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22656234
Drug: Rituximab (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (750 mg/m(2) on days 1, 8, 15, and 22) and Temozolomide (150 mg/m(2) days 1-7 and 15-21) followed by consolidation Temozolomide (150-200 mg/m(2) × 5/28 days) and maintenance with Methylprednisolone (1 g IV every 28 days) until progression
Trial: 22658254
Drug: Early abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early abciximab administration before primary PCI
Trial: 22658254
Drug: Late abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late abciximab administration before primary PCI
Trial: 22659939
Drug: VO2peak >27.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VO2peak >27.3 ml/kg/min
Trial: 22659939
Drug: VO2peak ≤27.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VO2peak ≤27.3 ml/kg/min
Trial: 22661474
Drug: Ranibizumab (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (monthly intravitreal injections)
Trial: 22662137
Drug: Neutralizing antibodies
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralizing antibodies against EV71 in infants at 2 months
Trial: 22662137
Drug: Maternal antibody
RxNorm normalized name: Maternal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal antibody titers
Trial: 22662137
Drug: Seropositivity of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seropositivity of EV71 antibody in infants
Trial: 22664059
Drug: Flavopiridol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavopiridol (100 mg/m2 IV, 24 h infusion) and Cisplatin (60 mg/m2 IV)
Trial: 22665938
Drug: CRd (carfilzomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRd (carfilzomib 36 mg/m2, lenalidomide 25 mg/d, dexamethasone 40/20 mg)
Trial: 22668067
Drug: Saxagliptin 5
RxNorm normalized name: sAXagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 5 mg (single dose on day 1 and once daily on days 3-7)
Trial: 22668067
Drug: Saxagliptin 5
RxNorm normalized name: sAXagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 5 mg (single dose and once-daily doses for 5 days)
Trial: 22670903
Drug: Vismodegib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vismodegib (150 mg oral daily)
Trial: 22674435
Drug: L19-TNF ILP
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: L19-TNF ILP at 325 µg
Trial: 22674435
Drug: L19-TNF ILP
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: L19-TNF ILP at 650 µg
Trial: 22676070
Drug: Risperidone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (2 to 6 mg/day) for 6 months
Trial: 22676070
Drug: Risperidone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (2 to 6 mg/day) for 12 months
Trial: 22676070
Drug: Risperidone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (2 to 6 mg/day)
Trial: 22676070
Drug: Risperidone maintenance
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone maintenance treatment
Trial: 22677155
Drug: Lenalidomide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (20 mg) plus rituximab
Trial: 22681919
Drug: Gefitinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib (250 mg dose)
Trial: 22682146
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone therapy (Norditropin®)
Trial: 22685225
Drug: Secondary prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary prevention treatment for children diagnosed with RHD
Trial: 22693172
Drug: Anti-Müllerian hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-Müllerian hormone (AMH) at a cut-off value of 20 pmol/l
Trial: 22693229
Drug: Initial study
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial study vaccination with HIV load ≤400 copies/mL
Trial: 22695105
Drug: 10 μg vitamin
RxNorm normalized name: Vitamin G
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 μg vitamin D3 from fish oil capsules
Trial: 22695105
Drug: Multivitamin tablets
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multivitamin tablets
Trial: 22695254
Drug: Ridaforolimus (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridaforolimus (50 mg intravenous once weekly)
Trial: 22696176
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg inhaled salbutamol
Trial: 22698649
Drug: Mass eradication
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass eradication of H pylori infection (1-week clarithromycin-based triple therapy followed by 10-day levofloxacin-based triple therapy for treatment failures)
Trial: 22699667
Drug: Oral cGVHD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cGVHD (defined by NIH scale >2 points)
Trial: 22700780
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of auscultation and LUS
Trial: 22701542
Drug: Daily supervised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supervised exercise for two weeks
Trial: 22701615
Drug: Vandetanib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib (100 mg, 200 mg, or 300 mg daily) combined with cetuximab and irinotecan
Trial: 22707516
Drug: Bevacizumab, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab, 5 mg/kg or 10 mg/kg every 2 weeks
Trial: 22708895
Drug: Intravenous lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous lacosamide loading dose of 200 mg
Trial: 22708895
Drug: Intravenous lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous lacosamide loading dose of 300 mg
Trial: 22708895
Drug: Intravenous lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous lacosamide loading dose of 400 mg
Trial: 22713099
Drug: Ethinylestradiol 30μg-drospirenone
RxNorm normalized name: drospirenone and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinylestradiol 30μg-drospirenone 3mg plus metformin 1700 mg daily for 6 months
Trial: 25886678
Drug: Olanzapine treatment
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine treatment for 16 weeks
Trial: 22717743
Drug: AAV1-LPL(S447X) gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AAV1-LPL(S447X) gene therapy (alipogene tiparvovec) administered at 3 × 10(11) gc kg(-1) for cohorts 1 (n=2) and 2 (n=4) and 1 × 10(12) gc kg(-1) for cohort 3 (n=8). Immunosuppressants were also given to cohorts 2 and 3 for 12 weeks.
Trial: 22717743
Drug: AAV1-LPL(S447X) gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AAV1-LPL(S447X) gene therapy (alipogene tiparvovec)
Trial: 22719881
Drug: Bevacizumab monotherapy
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab monotherapy 10 mg/kg q14 d until intolerable toxicity or disease progression
Trial: 22721971
Drug: Rapamycin/IL-2 combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapamycin/IL-2 combination therapy
Trial: 22722717
Drug: Doxorubicin-eluting beads
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin-eluting beads (DEB) in transarterial chemoembolization (TACE), 100-300 μm beads loaded with ≤100 mg doxorubicin, up to four sessions within 6 months.
Trial: 22722755
Drug: Enzyme-linked immunospot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme-linked immunospot assay (within 2 years of drug reaction)
Trial: 22722778
Drug: ACTH gel
RxNorm normalized name: ACTH Gel
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH gel (80 units subcutaneously twice weekly for 6 months)
Trial: 24009220
Drug: ACTH gel
RxNorm normalized name: ACTH Gel
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH gel
Trial: 22723305
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of independent baseline predictors.
Trial: 22723326
Drug: Adjuvant endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant endocrine therapies (AET; leuprolide, tamoxifen, aromatase inhibitors)
Trial: 22723441
Drug: Insulin activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin activation of fatty acid uptake
Trial: 22727048
Drug: Basal-bolus therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal-bolus therapy with insulin detemir / insulin aspart
Trial: 22727048
Drug: Human NPH
RxNorm normalized name: INSULIN HUMAN NPH 100 UNIT/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human NPH insulin / human regular insulin
Trial: 22730482
Drug: Soluble tumour
RxNorm normalized name: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand
DrugBank: RR001 (DB17369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble tumour necrosis factor receptor (sTNFR-1)
Trial: 22731653
Drug: Eszopiclone 1
RxNorm normalized name: eszopiclone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eszopiclone 1 mg (elderly)
Trial: 22731653
Drug: Eszopiclone 2
RxNorm normalized name: eszopiclone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eszopiclone 2 mg (elderly)
Trial: 22731653
Drug: Eszopiclone 2
RxNorm normalized name: eszopiclone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eszopiclone 2 mg (nonelderly)
Trial: 22731653
Drug: Eszopiclone 3
RxNorm normalized name: eszopiclone 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eszopiclone 3 mg (nonelderly)
Trial: 22731653
Drug: Eszopiclone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eszopiclone (1 mg or 2 mg for elderly; 2 mg or 3 mg for nonelderly)
Trial: 22732334
Drug: HX575 (biosimilar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HX575 (biosimilar epoetin-α) administered intravenously aiming for hemoglobin (Hb) target of 10 - 12 g/dl
Trial: 22733017
Drug: Anti-plasma cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-plasma cell therapy
Trial: 22733373
Drug: Palonosetron 0.25
RxNorm normalized name: palonosetron 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron 0.25 mg IV 30 min before chemotherapy
Trial: 22734012
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m² plus cisplatin 60 mg/m² (day 1), followed by oral capecitabine 1875 mg/m² divided into two doses (days 1-14) every 3 weeks; three cycles preoperatively and three cycles postoperatively
Trial: 22734119
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus acupuncture treatment
Trial: 22734817
Drug: Anemia (defined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anemia (defined as Hb <11.0 g/dl in children <5 years or <11.5 g/dl in children 5-12 years)
Trial: 22735035
Drug: Exenatide administration
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide administration for an average of 84 ± 5 days
Trial: 22735035
Drug: Exenatide administration
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide administration
Trial: 22736604
Drug: Novel cancer
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel cancer cell vaccine for prostate cancer
Trial: 22736604
Drug: Intravenous aciclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous aciclovir and dexamethasone
Trial: 22742742
Drug: Certoparin 3,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Certoparin 3,000 IU i.v. with additional titration steps of 600 IU and/or continuous infusion if necessary
Trial: 22742881
Drug: IV busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV busulfan (0.8-1.2 mg/kg) administered four times daily for 4 days
Trial: 22742881
Drug: Oral busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral busulfan (1.45-1.55 mg/kg) administered four times daily for 4 days
Trial: 22744195
Drug: PEG-3350 mixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-3350 mixed with 1.9 L of Gatorade
Trial: 22748805
Drug: n-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 polyunsaturated fatty acid (PUFA) supplementation (3 g/day)
Trial: 22750015
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D(3) supplementation (0 to 4000 IU/d)
Trial: 22751081
Drug: Natrelle Style
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natrelle Style 410 implants
Trial: 22751595
Drug: IA etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IA etanercept injections (12.5 mg, 4 injections every 2 weeks)
Trial: 22752026
Drug: Insulin-mediated myocardial
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-mediated myocardial glucose disposal assessed with 2-deoxy-2-[(18)F]fluoroglucose PET.
Trial: 22759444
Drug: Progressors (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressors (n = 39) defined as those with serial LAVI change ≥3.5 mL/m(2) and baseline LAVI between 20 and 34 mL/m(2)
Trial: 22760567
Drug: Insulin (during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (during hyperinsulinemic euglycemic clamp)
Trial: 22761257
Drug: Leukotriene B4
RxNorm normalized name: Leukotriene B4
DrugBank: Leukotriene B4 (DB12961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukotriene B4 (LTB4) at 10 ng/ml in OSA patient monocytes
Trial: 22761653
Drug: Sunitinib (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (37.5 mg daily) and IGRT (50 Gy)
Trial: 22762314
Drug: Eltrombopag (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag (50 mg daily, increased to 150 mg as needed for 12 weeks)
Trial: 22763609
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m² intravenously every 21 days until progression or unacceptable toxicity
Trial: 22766223
Drug: Parathyroid hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parathyroid hormone (PTH) at 100 μg/day for 28 days
Trial: 22766247
Drug: MF59-adjuvanted A/H1N1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted A/H1N1 influenza vaccine, Focetria
Trial: 22766773
Drug: Enzastaurin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzastaurin (500 mg QD, 250 mg BID, 375 mg BID, 500 mg BID, 750 mg BID) in combination with Bevacizumab (5 mg/kg every 2 weeks, 10 mg/kg every 2 weeks, or 15 mg/kg every 3 weeks)
Trial: 22766773
Drug: Enzastaurin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzastaurin (750 mg BID) in combination with any tested dose/schedule of Bevacizumab
Trial: 22767640
Drug: B lymphocyte
RxNorm normalized name: B lymphocyte antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B lymphocyte depletion therapy (iv rituximab 1 g on days 1 and 15 after 125 mg iv methylprednisolone)
Trial: 22768052
Drug: AMA1 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMA1 vaccine (10 µg) with Alhydrogel
Trial: 22768052
Drug: AMA1 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMA1 vaccine (50 µg) with Alhydrogel
Trial: 22768052
Drug: AMA1 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMA1 vaccine (10 µg) with Montanide ISA 720
Trial: 22768052
Drug: AMA1 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMA1 vaccine (50 µg) with Montanide ISA 720
Trial: 22768052
Drug: AMA1 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMA1 vaccine (10 µg) with AS02
Trial: 22768052
Drug: AMA1 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMA1 vaccine (50 µg) with AS02
Trial: 22769055
Drug: 600mcg sublingual
RxNorm normalized name: ABSTRAL 600mcg Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mcg sublingual misoprostol
Trial: 22769055
Drug: 800mcg sublingual
RxNorm normalized name: ABSTRAL 800mcg Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800mcg sublingual misoprostol
Trial: 22770644
Drug: Oral linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral linezolid (600 mg q12h)
Trial: 22770644
Drug: Intravenous vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous vancomycin (15 mg/kg q12h)
Trial: 22776426
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with three HLA-A24-binding peptides (TTK, LY6K, IMP3) administered with IFA weekly
Trial: 22777094
Drug: MF59-adjuvanted A/H5N1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted A/H5N1 influenza vaccine booster dose
Trial: 22777131
Drug: Levetiracetam (55
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (55 mg/kg/d) for 30 days starting within 8 hours after injury
Trial: 22777131
Drug: Levetiracetam (55
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (55 mg/kg/d)
Trial: 22777131
Drug: Levetiracetam treatment
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam treatment group
Trial: 22777131
Drug: Levetiracetam treatment
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam treatment
Trial: 22777623
Drug: Ambrisentan 5
RxNorm normalized name: ambrisentan 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan 5 mg or 10 mg once daily for 24 weeks
Trial: 22780885
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (daily dose of 3533 IU, increased to 8533 IU after the first five participants) and 530 mg elemental Ca daily
Trial: 22782731
Drug: No proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No proton pump inhibitor use
Trial: 22782731
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor use (self controlled case series)
Trial: 22782731
Drug: Other 2C19
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other 2C19 inhibitors/non-inhibitors (self controlled case series)
Trial: 22785351
Drug: ERBB network
RxNorm normalized name: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY, BIPARATOPIC (TARGETING TWO DIFFERENT NON-OVERLAPP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERBB network therapies, specific details not available
Trial: 22788989
Drug: Neoadjuvant dose-escalated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant dose-escalated IMRT (50-56 Gy) followed by surgery and IORT (10-12 Gy)
Trial: 22792000
Drug: Tapentadol prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol prolonged release (50-250 mg bid)
Trial: 22792000
Drug: Tapentadol prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol prolonged release and immediate release (50 mg ≤twice/day; ≥4 hours apart)
Trial: 22794786
Drug: Viral gene
RxNorm normalized name: Gp100 adenoviral gene therapy
DrugBank: GP-100 antigen (DB14800)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viral gene therapy
Trial: 22798253
Drug: Non-exercise control
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-exercise control treatment (n=92)
Trial: 22801963
Drug: GCLAC (clofarabine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GCLAC (clofarabine, high-dose cytarabine, and granulocyte colony-stimulating factor)